(MENAFN- GlobeNewsWire - Nasdaq) HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 – December 2, 2021. Aravive's presentation will be available for viewing on November 22, 2021 at 10:00 AM ET. Aravive will also participate in virtual one-on-one meetings on December 1, 2021.
This conference is being held virtually, and a live webcast will be accessible on the Events & Presentations page of . An archived replay of the webcast will be available for 90 days following the webcast.
Aravive, Inc. is a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers. The Company is currently evaluating its lead therapeutic, batiraxcept (AVB-500), in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit .
Luke Heagle, Real Chemistry
Aulani Capuchin, Real Chemistry
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.